Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PYNNACLE: PC14586 in advanced solid tumors with TP53 Y220C mutation
2023-504251-27-00Phase 2Authorised
- Sponsor
- PMV Pharmaceuticals, Inc.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of rezatapopt in Nonhematologic neoplasms, ovarian cancer and castration-resistant prostate cancer (CRPC), sponsored by PMV Pharmaceuticals, Inc. Primary endpoints: Overall response rate across all cohorts and Overall response rate in ovarian cancer cohort. Planned start May 2024; status: authorised.
02
Drugs
rezatapopt
03
Conditions
Nonhematologic neoplasmsovarian cancercastration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2023-504251-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504251-27-00.